ABSTRACT As natural components of human milk, arachidonic and docosahexaenoic acids play important roles in neonatal development; thus, addition of these fatty acids to infant formula has been suggested. This study examined the effects of supplementation of in fant formula with microbial sources of either arachidonate or docosahexaenoate or both on accretion of these fatty acids in phospholipids and subsequent modulation of eicosanoid production in neonatal pig lung. One-day-old piglets received for 25 d one of four diets (n = 5): 1) standard diet containing a fat blend similar to that of conventional infant formula, 2) diet containing 0.9 g/100 g of total fatty acids as arachidenate, 3) diet containing 0.7 g/100 g as docosahexae noate, or 4) a diet containing both 1.0 g/100 g as arachidonate and 0.8 g/100 g as docosahexaenoate.
Arachidonate supplementation resulted in 30-60% significantly greater arachidonate in lung phosphatidylethanolamine and phosphatidylcholine.
In phosphatidylinositol, however, arachidonate was resistant to di etary manipulation. Accretion of docosahexaenoate in all three phospholipid classes was 2.6-to 4.7-fold greater in docosahexaenoate-supplemented groups than in the standard group. Inclusion of arachidonate in the diet augmented both prostacyclin and thromboxane production by 25 to 35%. Docosahexaenoate supplementation resulted in the least eicosanoid pro duction among the treatments, and significant sup pression was observed for thromboxane when supple mentation with both fatty acids was compared with supplementation with arachidonate alone. Thus, di etary arachidonic acid and docosahexaenoic acid at concentrations only slightly greater than those found in human milk tended to exercise opposing effects on lung eicosanoid production.
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â€¢arachidonic acid â€¢docosahexaenoic acid â€¢eicosanoid â€¢infant formula â€¢piglets Linoleic acid [LA, [5] [6] ] and a-linolenic acid [LNA, ] are dietary precursors for the (n-6) and (n-3) long-chain polyunsaturated fatty acids (LCPUFA) and are elongated to arachidonic acid [AA, ] and docosahexaenoic acid [DHA, ]; respec tively. Current infant formulas in North America con tain LA and LNA in amounts equal to or greater than the amounts found in breast milk, but, unlike breast milk, conventional formulas are devoid of LCPUFA (Jensen et al. 1992) .
During perinatal development, DHA accumulates in the synaptic membranes of the brain and photoreceptor rod outer segments of the retina (Innis 1991) . Deficiency of dietary (n-3) fatty acids during this period results in poor DHA accretion in the brain and retina, subse quently leading to altered neurological and visual func-tion in young rats (Anderson and Connor 1988, Yamamoto et al. 1987 ) and rhesus monkeys (Neuringer et al. 1986 ). Both preterm and term infants fed conventional infant formula exhibit impaired DHA accretion in red blood cell phosphatidylethanolamine (PE) and phosphatidylcholine (PC) as compared with breast-fed infants (Carlson et al. 1986 , Putnam et al. 1982 . Similarly, DHA in the cerebral cortex of breast-fed infants is greater than that for formula-fed infants (Farquharson et al. 1995 , Makrides et al. 1994 . These findings have formed the basis for the suggestion that dietary preformed sources of DHA may be required in the neonatal period when needs of the rapidly developing infant cannot be met by the elongation and desaturation of LNA.
In an attempt to supply the developing infant with preformed DHA, several investigators have used ma rine oil as a source of (n-3) LCPUFA in infant formula (Carlson et al. 1991 , 1992a and 1992b , Clandinin et al. 1992 . Carlson et al. (1991 Carlson et al. ( , 1992b Carlson et al. ( and 1993 reported that preterm infants fed formulas supplemented with marine oil showed greater phospholipid DHA in red blood cells and plasma and demonstrated improved vi sual function; however, the infants receiving marine oil supplementation exhibited poorer growth, which was correlated with a compromised AA status. Thus, supplementation of infant formula with AA as well as DHA was suggested.
Like DHA, AA accumulates in brain phospholipids during fetal and postnatal development (Sastry et al. 1985) , and the postnatal decline in erythrocyte AA is greater in formula-fed infants than in breast-fed infants (Carlson et al. 1986 ). Arachidonic acid, however, is im portant not only as a component of membrane phos pholipids, but also as a precursor of eicosanoids throughout the body. The metabolic interactions of di etary AA with DHA and the subsequent effects on tis sue eicosanoid production have not been studied in a neonatal model.
Because of the physiological similarities to human infants, neonatal pigs are a suitable animal model for term-gestation infants (Innis 1993 ). In the current study, the neonatal pig was used to study the effects of dietary LCPUFA on phospholipid fatty acid profile and eicosanoid production. Microbial sources of AA or DHA or a combination of both were incorporated into liquid diets at concentrations slightly greater than those normally found in breast milk. The objective was to examine 1} whether the addition of AA, DHA or a combination of both to the diet would influence accre tion of lung phospholipid (n-6) and (n-3) fatty acids and 2 ) whether addition of AA, DHA or a combination of both would modulate eicosanoid production by incu bated lung tissue.
Lung eicosanoids were measured because of their importance in the neonatal period. Evidence exists that gene expression of pulmonary cyclooxygenase-I, as well as prostacyclin, rises during late gestation and early newborn life (Brannon et al. 1994 ). Prostacyclin, a po tent vasodilator and bronchodilator, is believed to be critical in successful cardiopulmonary transition and function in the newborn (Leffler et al. 1984) . On the other hand, thromboxane A2 has effects that generally oppose those of prostacyclin, and therefore the balance of these two compounds is believed to determine the resulting physiological activity. Thus, the effects of di etary AA and DHA on both of these eicosanoids were studied in the current experiment.
MATERIALS AND METHODS
Animals. Twenty-five male piglets (Yorkshire X Landrace sows bred to Duroc boars) of normal gestation were obtained at 1 d of age from the Swine Nutrition Unit of the Alabama Agricultural Experimental Station, Auburn University (Auburn, AL). Littermates, weighing at least 1.36 kg from each of five litters, were assigned randomly to receive four formulas (n = 5). Additionally, one piglet from each of the five litters remained with the sow to serve as the naturally reared group (SOW). The size of the remaining litter was standardized to five by cross-fostering if necessary. The 20 formula-fed neo natal pigs were individually housed in metal cages at 35Â°Cin a temperature-controlled room and artificially fed for 25 d. Passive immunity was provided by adminis tration of bovine immunoglobulin concentrate (LitterMakerâ"¢, Protein Technology, Petaluma, CA) to the formula for the first 72 h of feeding. All animal protocols were approved by the Auburn University Institutional Animal Care and Use Committee.
Diets. The formulas were prepared using a non-fat sow's milk replacer (Pet-Ag, Elgin, IL) at 20 g solids/ 100 g total liquid formula. Fat blends containing AA and DHA were added such that the formula contained 20% of the solids as fat. Thus, 1000 g of formula con tained 160 g of non-fat milk replacer, 40 g of oil and 800 g of water. Dietary treatments were a standard diet (STD) and diets supplemented with either AA (STD + AA), DHA (STD + DHA), or both AA and DHA (STD + BOTH). The fatty acid composition of the standard (STD) diet was similar to that of current infant formula. Microbial sources of lipids (Martex Biosciences, Co lumbia, MD) were added to the STD diet such that the LCPUFA were present in the following concentrations (g/100 g fatty acids): STD + AA, 0.9 as AA; STD + DHA, 0.7 as DHA; and STD + BOTH, 1.0 as AA plus 0.8 as DHA. The complete fatty acid compositions of the fats in the dietary treatments and sow's milk are shown in Table 1 . The amount of supplemental AA was equivalent to approximately 0.4% energy or 100 mg/kg body wt per day,-the amount of supplemental DHA was equivalent to approximately 0.3% energy or 80 mg/kg body wt per day. The formula diets were prepared within 24 h of feeding and stored at 4Â°C. The formulas were warmed in a water bath immediately before they were fed, and consumption was recorded at every feeding. The piglets were weighed at 4-d inter vals. Collection of sow's milk was performed on d 12 of lactation. Because corn was the major source of fat in the diet of the sows, the sow's milk was relatively high in (n-6) fatty acids (LA = 12.7 g/100 g fatty acids, AA = 0.7 g/100 g fatty acids) and low in (n-3) fatty acids (LNA = 0.6 g/100 g fatty acids, DHA = 0.04 g/ 100 g fatty acids) ( Table 1) . Lung fatty acid analysis. After 25 d of feeding, ani mals were killed by injection of sodium pentobarbital (88 mg/kg; Beuthanasia-D Special, Schering-Plough Animal Health, Kenilworth, NJ), and the lungs were removed. Approximately l g of tissue was homoge nized in 10 mL of deionized water. Total lipids of the homogenate were extracted by the method of Folch et al. (1957) with 20 mL of chloroform-methanol (2:1, v/ v, with 50 mg/L butylated hydroxytoluene added). Lung phospholipids were separated by high performance TLC (Silica Gel HL; Analtech Inc., Newark, DE) using a chloroform-methyl acetate-n-propanol-methanol-2.5 g/L aqueous potassium chloride (25:25:25:10:8.5, by volume) solvent system as described by Vitiello and Zanetta (1978) . The phospholipids, PE, PC and phosphatidylinositol (PI), were identified by comparison with authentic standards (Matreya, Inc., Pleasant Gap, PA). Phospholipid fractions were scraped immediately from the TLC plate, and the fatty acids were derivatized using 12 g/100 g boron trifluoride-methanol (Supelco Inc., Bellefonte, PA) and heated in a 110Â°C dry hot block for 30 min. Methylated fatty acids were extracted with pentane-water (2:1, v/v). Fatty acid methyl ester (FAME) derivatives were dissolved in dichloromethane and analyzed using a gas Chromatograph (model 3400, Varian, Sugar Land, TX) equipped with a DB225 fused silica capillary column (0.25 mm x 30 m; J&W Scien tific, Folsom, CA) and linked to a model 4400 integrator (Varian). The temperatures of the injector and flame ionization detector were maintained at 250Â°C and 270Â°C, respectively. The column temperature was pro grammed to increase from 120Â°Cto 170Â°Cat a rate of 5Â°C/min and from 170Â°Cto 225Â°Cat a rate of TC/min.
Helium was used as carrier gas. Fatty acid methyl esters were identified by comparison of relative retention times with commercial FAME standards (Matreya) or with a secondary standard of menhaden oil obtained from the NOAA Laboratory (Charleston, SC).
Analysis of lung eicosanoids. Approximately 0.4-0.5 g of fresh lung was rinsed with saline, weighed to the nearest 0.01 mg, minced in a defined manner (100 strokes of a scalpel blade) and put into an Erlenmeyer flask containing 10 mL of preincubated Kreb's-Ringer bicarbonate buffer. Triplicate samples of lung tissue were incubated in an atmosphere of 95% oxygen and 5% carbon dioxide with shaking at 37Â°Cin a water bath. The reaction was stopped by addition of 1 mol/ L HCl to obtain a pH of 3.5 to 4.0. Eicosanoids were extracted twice from the incubation medium using 20 mL of ethylacetate. The ethylacetate fractions were pooled, evaporated to dryness and then redissolved in ethanol, and samples were stored at -80Â°C until analy ses. Immediately prior to analysis by RIA, the samples were evaporated and redissolved in gel PBS. Extraction efficiency was measured by addition of 36 Bq of [3H]-prostaglandin Fia (Du Pont NEN Research Products, Boston, MA) prior to extraction. The average extraction recovery was 93%.
Eicosanoids were analyzed using [H3] RIA kits (Du Pont NEN), for assay of 6-keto-prostaglandin FlÂ£t (6-keto-PGF]a), the stable metabolite of prostacyclin, and thromboxane B2 (TXB2), the stable metabolite of thromboxane A2. Procedures were based on the instruc tion manual of the RIA kits with only minor modifica tions. All the reagents were reconstituted with distilled water, stored in the refrigerator and used within 1 mo. All samples and standards were assayed in duplicate. The assay consisted of 100 //L of lung extract, 100 (Â¿L of antibody, 100 Â¿zL of tracer and enough assay buffer (50 mmol/L phosphate buffer, pH 6.8) to give a total volume of 500 //L. The mixtures were incubated for 18 h at 4Â°C. Then, 500 Â¿Â¿L of charcoal suspension (0.5 mL of 0.5% Norit A in 10 mmol/L phosphate buffer, pH 6.8, with 0.5% Dextran T-70) was added to each tube. The samples were placed in an ice bath for 10 min and then centrifuged for 15 min at 4Â°Cat 1300 x g. Radioactivity of the supernatant was determined using a Packard Liquid Scintillation Analyzer (1600TR model, Packard Instrument, Downers Grove, IL). Data reduction was performed with Riasmart (Packard In strument).
Statistical analysis. Data were analyzed by the De partment of Research Data Analysis of the Alabama Agricultural Experiment Station of Auburn University. Differences in weight gain and formula consumption were tested by repeated measures ANO VA. Differences among treatments in the fatty acids and eicosanoid data among treatments were tested by ANOVA proce dures. Significant differences among treatment means were determined using least significance difference analysis (P = 0.05). The Statistical Analysis System computer program (SAS 1989 , SAS/STAT Version 6, SAS Institute, Cary, NC) was used to analyze the data. Variation in the data is expressed as common standard error of the mean (pooled SEM).
RESULTS

Body weight and formula consumption of piglets.
The initial mean body weights (1.7-1.8 kg) among the five treatment groups were not significantly different. After 25 d of dietary treatment, both the final weight (9.8-10.4 kg) and weight gain (8.0-8.6 kg) of the four dietary treatment groups (STD, STD + AA, STD + DHA, STD + BOTH) were significantly greater than those of the naturally reared group (SOW), which had a final weight of 7.8 kg and a weight gain of 6.1 kg. No significant differences in formula consumption or in the final body weight due to diet were observed among the four dietary treatment groups during the experi mental period.
Lung fatty acid composition in phosphatidylethanolamine. The pattern of fatty acids in PE is shown in Table 2 . Groups receiving treatments containing AA (STD + AA, STD + BOTH, SOW) exhibited similar AA accretion in lung phospholipid PE. The piglets receiv ing AA-containing treatments all exhibited signifi cantly greater AA than the two groups receiving treat ments containing no AA (STD, STD + DHA). The amount of AA in lung phospholipid PE from piglets fed the STD + DHA diet was the least and was signifi cantly less than that of piglets fed the STD diet. The enrichment of tissue AA due to dietary supplemental AA was accompanied by a 35% reduction in LA. Simi larly, lower values for 20:3(n-9) and 20:3(n-6) were also observed in treatment groups fed AA. The elongation products of AA, 22:4(n-6) and 22:5(n-6), were signifi cantly greater in piglets fed diets containing AA alone or with a very small amount of DHA (STD + AA, SOW) compared with those fed STD, but greater amounts of these two fatty acids were not observed in piglets fed diets supplemented with AA in combination with DHA compared with those fed STD.
Piglets fed formula supplemented with DHA (STD + DHA and STD + BOTH) exhibited 3.5-to 5.5-fold greater PE-DHA than the piglets receiving unsupplemented treatments. Linolenic acid was present in small amounts and did not reflect differences in treatment groups. Piglets fed diet supplemented with DHA alone had greater EPA than those fed STD. Piglets fed diets containing AA (STD + AA, STD + BOTH, SOW) exhib ited significantly lower EPA than those fed STD. An inhibitory effect of supplementation with DHA on AA elongation to C22 derivatives was observed. Signifi cantly lower lung PE 22:4(n-6) and 22:5(n-6) were ob served when the STD + BOTH group was compared with the STD + AA group.
Treatments including AA resulted in significantly greater total (n-6) fatty acids compared with treatments containing no AA. Supplementation with AA resulted in a significant elevation in total (n-6) fatty acids (STD + AA vs. STD; STD + BOTH vs. STD + DHA); how ever, supplementation with DHA resulted in a signifi cant reduction in (n-6) total fatty acids (STD + DHA vs. STD; STD + BOTH vs. STD 4-AA). Total (n-3) fatty acids in piglets fed STD + BOTH and STD + DHA were 70-120% greater than in those fed the STD formula.
In lung PE, total saturated fatty acids were not differ- (n-6)18:3 (n-3)20:120:2 |n-6)20:3 |n-9)20:3 |n-6)20:4 (n-6)20:5 (n-3)22:4 (n-6)22:5 (n-6)22:5 (n-3)22:6 (n-3)SAT7MUFA8PUFA9Z
(n-6)10Z (n-3)H(n-6)/(n-3)12(n-6)/(n-3|, 1 Data are presented as means. Means in a row with different superscripts are significantly different based on least significant difference (P = 0.05). NS = not significantly different (p > 0.05).
2 Fatty acid composition of standard diet (STD) is similar to that of conventional infant formula. Diet abbreviations = AA, arachidonic acid; DHA, docosahexaenoic acid; BOTH, arachidonic acid and docosahexaenoic acid; SOW, naturally reared group.
Spooled standard error of the mean based on n = 5, except for 14:0, 18:3 (n-3), 20:1, 20:5 (n-3) and 22:5 (n-6), in which there was at least one missing value. 4 tr = trace. 5 Includes 16:1 (n-9) and 16:1 (n-7). 6 Includes 18:1 (n-9) and 18:1 (n-7). 7 Total saturated fatty acids. 8 Total monounsaturated fatty acids. 9 Total polyunsaturated fatty acids (C sz 18). 10Total (n-6) fatty acids. 11Total (n-3) fatty acids. 12Total (n-3) fatty acids/total (n-6) fatty acids. 13 Arachidonic acid/linoleic acid. 14Arachidonic acid/docosahexaenoic acid.
ent among treatment groups, and total monounsatu rated fatty acids were greater in piglets receiving STD and STD + DHA. In the naturally reared piglets (SOW), 16:1 was significantly greater and 18:1 was significantly less than in those given the other four treatments. Table  3 . As in PE, AA in PC was responsive to dietary supple mentation. Piglets fed diets containing AA (STD + AA, STD + BOTH, SOW) exhibited greater AA than those fed diets containing no AA (STD and STD + DHA); however, the larger value observed in piglets fed STD -I-BOTH was not significantly different from that in piglets fed STD. Likewise, elevation of tissue AA at the expense of LA was observed in PC as in PE. The amount of 22:4(n-6) was significantly greater in piglets fed STD + AA and in the SOW group than in those fed the STD diet but was similar among animals fed STD + DHA, STD + BOTH and STD.
Lung fatty acid composition in phosphatidylcholine. The pattern of fatty acids in PC is shown in
Accretion of DHA in lung PC was also responsive (n-6|18:3 |n-3)20:1 .20:2 (n-6)20:3 (n-9)20:3 (n-6)20:4 (n-6)20:5 (n-3)22:4 (n-6)22:5 (n-6)22:5 (n-3)22:6 (n-3)SAT6MOFA?PUPAÂ»Z (n-6|9I (n-3)10|n-6)/(n-3)H|n-6)/(n-3), 1 Data are presented as means. Means in a row with different superscripts are significantly different based on least significant difference (P = 0.05). NS = not significantly different (P > 0.05).
3 Pooled standard error of the mean based on n = 5, except for 20:3 |n-9), 20:5 (n-3), 22:5 (n-6) and 22:5 (n-3), in which there was at least one missing value.
4 Includes 16:1 (n-9) and 16:1 (n-7). 5 Includes 18:1 (n-9) and 18:1 (n-7). 6 Total saturated fatty acids. 7 Total monounsaturated fatty acids. 8 Total polyunsaturated fatty acids (C a 18). 9 Total (n-6) fatty acids. 10Total (n-3) fatty acids. 11Total (n-3) fatty acids/total (n-6) fatty acids. 12Arachidonic acid/linoleic acid. 13Arachidonic acid/docosahexaenoic acid.
to dietary changes as in PE. The amount of DHA was 2.6-fold and 4.7-fold greater in groups fed STD + BOTH and STD + DHA, respectively, compared with unsupplemented groups. Piglets fed diet supplemented with DHA alone had the greatest 18:3(n-3); on the other hand, the naturally reared group exhibited the lowest 18:3(n-3). Supplementation with DHA alone resulted in greater 20:5(n-3) than in the other treatments. The other (n-3) fatty acid, 22:5(n-3), was present in rela tively small amounts and was similar among the five treatment groups.
Supplementation with small amounts of LCPUFA re sulted in similar total polyunsaturated fatty acids and total (n-6) fatty acids among the five treatment groups. Accretion of the total (n-3) fatty acids, however, was significantly greater in piglets fed STD -I-DHA and STD + BOTH than in those fed STD, STD + AA or SOW. Only minor differences were observed in saturated fatty acids and monounsaturated fatty acids among the five treatment groups. The fatty acids 14:0, 18:1 and 20:1 were significantly less in naturally reared piglets than in those from the other four treatment groups. On the other hand, 16:0 and 16:1 were significantly greater in the SOW group. (n-6)20:3 (n-9)20:3 (n-6)20:4 (n-6)20:5 |n-3)22:4 (n-6)22:5 (n-6)22:5 (n-3)22:6 (n-3)SATÂ«MUFA9PUFA10Z(n-6)HL (n-3)12(n-6|/(n-3)13(n-6)/(n-3), 2 Fatty acid composition of standard diet (STD) is similar to that of conventional infant formula. Diet abbreviations = AA, arachidonic acid; DHA, docosahexaenoic acid; BOTH, arachidonic acid and docosahexaenoic acid; SOW, naturally reared group.
3 Pooled standard error of the mean based on n = 5, except for 14:0, 16:1, 18:3 (n-3), 20:1, 20:2, 20:3 (n-9|, 20:5 (n-3), 22:5 (n-6) and 22:5 (n-3), in which there was at least one missing value.
4 tr = trace. 5 ND = not detected. 6 Includes 16:1 (n-9) and 16:1 (n-7). 7 Includes 18:1 (n-9| and 18:1 (n-7). 8 Total saturated fatty acids. 9 Total monounsaturated fatty acids. 10Total polyunsaturated fatty acids (C a 18). 11Total (n-6) fatty acids. 12Total (n-3) fatty acids. 13Total (n-3) fatty acids/total (n-6) fatty acids. 14Arachidonic acid/linoleic acid. 15Arachidonic acid/docosahexaenoic acid.
Lung fatty acid composition in phosphatidylinosi tol. Differences in the pattern of fatty acids in PI among treatment groups are shown in Table 4 . The accretion of AA and LA was similar among treatment groups. Although AA and LA remained constant, the AA elongation product, 22:4(n-6), was responsive to di etary changes. In STD + AA treatments and in the SOW, 22:4(n-6) was 50-150% greater than in piglets fed STD; the greater values for 22:4(n-6) were accompa nied by reductions in 20:3(n-9) and 20:3(n-6). No aug mentation was observed for STD + BOTH.
The amount of DHA in PI was also dependent upon dietary DHA as observed in PE and PC. The amount of DHA in piglets fed STD + DHA and STD + BOTH was 3.6-fold and 2.7-fold greater than in piglets fed STD; both STD + AA and SOW groups exhibited levels of DHA similar to that in piglets fed STD. Addition of DHA resulted in the least 22:4(n-6); AA supplementa tion in combination with DHA resulted in a level of 22:4(n-6) in piglets fed STD + BOTH that was similar to that in piglets fed STD + DHA.
There were significantly greater total (n-3) fatty 2 Abbreviations used: AA, arachidonic acid, DHA docosahexaenoic acid; 6-keto-PGFia, 6-keto-prostaglandin Fia (stable metabolite of prostacyclin); TXBj, thromboxane 62 (stable metabolite of thromboxane A2).
3 Fatty acid composition of standard diet (STD) is similar to that of conventional infant formula. Diet abbreviations = AA, arachidonic acid; DHA, docosahexaenoic acid; BOTH, arachidonic acid and docosahexaenoic acid; SOW, naturally reared group. acids in treatment groups supplemented with DHA compared with the unsupplemented groups. The total (n-6) fatty acids as well as total saturated, monounsaturated and polyunsaturated fatty acids were similar among treatment groups.
Lung prostacyclin production. The production of 6-keto-PGFla; the stable metabolite of prostacyclin, is shown in Table 5 . The production of 6-keto-PGFla was greater in groups fed AA-containing diets (STD + AA, STD + BOTH, SOW) than in those fed diets containing no AA (STD, STD + DHA), but the differ ence was significant only for STD + AA. This value was 33% greater in the STD + AA group than in the STD group. Addition of DHA tended to reduce 6-keto-PGFla (STD + AA vs. STD -I-BOTH; STD vs. STD + DHA). The STD + DHA group exhibited the least 6-keto-PGFia production and this was signifi cantly less than in groups fed diets containing AA. The 6-keto-PGFla production in the STD + BOTH group was intermediate between that of the STD + AA and STD + DHA diet groups but was signifi cantly different only from that for STD + DHA. The SOW group was similar to the other groups fed diets containing AA.
Lung thromboxane production. The production of TXB2, the stable metabolite of thromboxane A2/ is shown in Table 5 . In general, production of TXB2was similar to that of prostacyclin in response to dietary manipulation. Addition of AA alone resulted in greater TXB2production compared with the STD group; how ever, addition of AA in the presence of DHA did not result in a significantly greater value compared with STD. Thromboxane B2, like prostacyclin, was lowest in the STD + DHA group, but the value was similar to that of the STD group. Addition of AA along with DHA significantly reduced TXB2 production (STD + AA vs. STD + BOTH) and resulted in TXB2production similar only to that in piglets fed STD. The SOW group exhibited TXB2production similar to that of piglets fed STD + AA.
DISCUSSION
Dietary AA at a concentration only slightly greater than that normally found in human milk markedly elevated AA accumulation in lung PE and PC, but not PI, and resulted in greater prostacyclin and thrombox ane production by incubated lung tissue. Except for the work of Seyberth et al. (1975) , the impact of dietary AA on eicosanoid production has not been investigated until recently. Whelan et al. (1993) found that addition of moderate amounts of AA as the ethyl ester to the diet resulted in elevated production of prostaglandin E2 by Syrian hamster peritoneal macrophages and TXB2 by platelets in response to in vitro stimulation. Simi larly, in rats fed a high fat diet supplemented with AA as ethyl ester, Mann et al. (1994) found greater aorta 6-keto PGFia production and more urinary metabolites of prostacyclin than in the unsupplemented animals. A clear effect of AA supplementation was observed in the present study, even though the concentration of dietary AA (0.36% energy) was less than that used in previous studies. Moreover, use of microbial oils en abled administration of dietary AA in the triglycÃ©ride form, a more physiological form than ethyl ester used by other investigators (Ikeda et al. 1994 , Mann et al. 1994 , Whelan et al. 1993 .
The significant elevation of eicosanoids observed in response to dietary AA can be explained in part by higher AA in lung PE and PC. Production of TXB2was significantly correlated (P ==0.0065) with AA in both PE (r = 0.53) and PC (r = 0.59), but not PI. Production of PGI2 was correlated with AA only in PE (i = 0.54). Thus, PE and PC, but not PI, seem to provide AA as substrate for lung eicosanoid synthesis that is subject to dietary manipulation. The fact that PI is more resis tant to dietary manipulation has been observed by sev eral investigators, including Naughton et al. (1988) .
Other investigators have observed changes in the (n-6) fatty acid profile in response to dietary treatment with supplemental AA. In agreement with the present study, Clandinin et al. (1992) reported that supplemen tation of formula with AA at 0.2% of fatty acids sig nificantly elevated plasma phospholipid AA in preterm infants compared with those fed an unsupplemented formula. Similarly, in animal studies, Whelan et al. (1992 and 1993) demonstrated greater AA incorporation into phospholipids of rat liver, lung, heart, spleen, kid ney and testes when a moderate amount of AA was included in the diet. In addition to AA, other (n-6) fatty acids were influenced by dietary AA. Phospholipid 18:2(n-6) was reduced and 22:4(n-6) was elevated in the studies of Whelan et al. (1992 and 1993) . A similar fatty acid profile was observed in the current experiment for AA supplementation (STD + AA). In light of known competition between (n-6) and (n-3) fatty acids, the relationship between AA and DHA supplementation on eicosanoid synthesis is of interest. Ikeda et al. (1994) reported that supplementation with DHA in the diet suppressed aortic 6-keto-PGFia pro duction compared with the control. In the current study, supplementation with DHA alone tended to sup press production of both eicosanoids in the lungs, and this suppression was statistically significant in TXB2 when STD + BOTH was compared with STD + AA. In most studies, inhibition of proinflammatory eicosa noid production by marine oil has been attributed to EPA (Simopoulos 1991) . Because marine oil is rich in both EPA and DHA, the observed effects could be due to either of these (n-3) fatty acids. In fact, Ikeda et al. (1994) found eicosanoid inhibition by dietary supple mentation with DHA but not EPA. Further, Largarde et al. (1992) reported that DHA seemed to be a stronger inhibitor of platelet aggregation than EPA. Thus, the relative effects of DHA vs. EPA on eicosanoid produc tion warrant further investigation.
Some investigators have postulated that retroconversion to EPA can partially account for antagonistic effects of DHA with AA. Retroconversion of DHA to EPA occurs in humans (Von Schacky and Weber, 1985) and rats (Schlenk et al. 1969) . Under conditions of the current experiment, a small amount of retroconversion may have occurred, as indicated by the fact that supple mentation with DHA significantly elevated EPA in PE and PC. However, the amount of EPA in lung phospho lipids is small in comparison with the amount of AA and therefore a significant effect of EPA formed by ret roconversion from DHA would not be expected. This effect would be particularly unlikely in light of the recent results of Li et al. (1994) , who showed that di etary AA abrogates the effects of dietary EPA when both are included in the diet in equal amounts. Recent research indicates that DHA may exercise effects inde pendently of EPA (Ikeda et al. 1994 , Largarde et al. 1992 , and thus the inhibition of thromboxane produc tion by DHA observed in the STD + BOTH vs. STD + AA comparison may be due to DHA itself.
In all three phospholipid classes, DHA level corre sponded to dietary supplementation.
Addition of DHA alone or in combination with AA resulted in 3.5-to 5.7-fold greater values in phospholipid DHA compared with unsupplemented treatments. In PE and PC, the greater value for DHA in the treatment containing both LCPUFA was not as pronounced as for supplementa tion with DHA alone. Thus, there is some evidence in the current study that AA supplementation inhibited phospholipid DHA accretion, but only when AA and DHA were fed together. Mann et al. (1994) and Whelan et al. (1993) also reported inhibition of tissue phospho lipid DHA by dietary AA in amounts greater than that used in current experiment. This inhibition of phos pholipid DHA accumulation by AA would be im portant if it occurred in the brain or the retina, where concentrations of DHA are high and where DHA is believed to serve a critical function. However, no inhi bition of retinal phospholipid DHA by dietary AA was observed in the current study (Craig-Schmidt et al. 1996) . In the lung phospholipid where DHA is present in smaller amounts compared with neural tissue, the significance of this inhibition is unknown.
Earlier efforts to supply DHA in infant formula used marine oil as the source of DHA (Carlson et al. 1991 , 1992a and 1992b , Clandinin et al. 1992 . Impaired AA status and concomitant poorer growth were found in infants receiving marine oil-supplemented formula compared with infants receiving a conventional formula (Carlson et al. 1992a ). The compromised AA status in these infants may have been due to competition between AA and the EPA in the marine oil-supplemented for mula. The use of microbial oils as sources of AA and DHA in this investigation allowed the study of supple mentation with these two fatty acids without the con founding effects of EPA. In the current study, limited inhibition of AA by DHA was observed. Supplementa tion with DHA resulted in the least AA in both PE and PC fractions of any group studied, but the reduction was significant only for PE. In studies in which DHA was fed to rats at much greater concentrations than in the current experiment (Ikeda et al. 1994 , Lien et al. 1994 ), a clear inhibition of AA accretion in the plasma, liver, aorta and platelets was observed. Because of the results of these investigators and the fact that dietary DHA at the lower concentrations used in the current study inhib ited AA incorporation into PE, it seems that DHA may have an antagonistic effect on AA. Thus, supplementa tion of infant formula with (n-3) LCPUFA, as preformed DHA, may not be desirable unless a source of dietary AA is also included in the formula.
On the basis of results using the piglet model, addi tion of both AA and DHA to infant formula seems to be beneficial for infants fed commercial formula. Both fatty acids are necessary to ensure adequate incorpora tion of DHA and AA into membrane phospholipids during the neonatal period and to provide AA for nor mal eicosanoid metabolism. Future investigations are necessary to identify the best balance between these two fatty acids.
